Aclaris Therapeutics, Inc.
ACRSUS売上高
$8M
百万USD
営業利益
$-76M
百万USD
純利益
$-65M
百万USD
ROE
-63.0%
最新FY
EPS
$-0.53
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $2M | $-29M | - |
| FY2021 | Q2 | $2M | $-18M | - |
| FY2021 | Q3 | $2M | $-21M | - |
| FY2021 | FY | $7M | $-91M | $-1.60 |
| FY2022 | Q1 | $1M | $-19M | $-0.31 |
| FY2022 | Q2 | $2M | $-21M | $-0.31 |
| FY2022 | Q3 | $19M | $-20M | $-0.30 |
| FY2022 | FY | $30M | $-87M | $-1.33 |
| FY2023 | Q1 | $3M | $-28M | $-0.42 |
| FY2023 | Q2 | $2M | $-30M | $-0.42 |
| FY2023 | Q3 | $9M | $-29M | $-0.41 |
| FY2023 | FY | $31M | $-88M | $-1.27 |
| FY2024 | Q1 | $2M | $-17M | $-0.24 |
| FY2024 | Q2 | $3M | $-11M | $-0.15 |
| FY2024 | Q3 | $4M | $-8M | $-0.11 |
| FY2024 | FY | $19M | $-132M | $-1.71 |
| FY2025 | Q1 | $1M | $-15M | $-0.12 |
| FY2025 | Q2 | $2M | $-15M | $-0.13 |
| FY2025 | Q3 | $3M | $-15M | $-0.12 |
| FY2025 | FY | $8M | $-65M | $-0.53 |
| FY2026 | Q1 | $2M | $-20M | $-0.15 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $10M | $4M | $6M | $7M | $30M | $31M | $19M | $8M |
| 営業利益 | $-49M | $-72M | $-135M | $-111M | $-51M | $-90M | $-90M | $-97M | $-142M | $-76M |
| 純利益 | $-48M | $-69M | $-133M | $-161M | $-51M | $-91M | $-87M | $-88M | $-132M | $-65M |
| 総資産 | $176M | $244M | $276M | $98M | $71M | $251M | $255M | $197M | $220M | $160M |
| 純資産 | - | - | - | - | - | - | - | - | - | - |
| 自己資本 | $169M | $225M | $215M | $70M | $38M | $197M | $198M | $157M | $156M | $103M |
| 営業CF | - | $-55M | $-101M | $-96M | $-39M | $-52M | $-68M | $-78M | $-20M | $-47M |
| EPS | - | - | - | - | - | $-1.60 | $-1.33 | $-1.27 | $-1.71 | $-0.53 |
| BPS | $6.50 | $7.29 | $5.21 | $1.68 | $0.73 | $3.22 | $2.96 | $2.22 | $1.44 | $0.85 |
| ROE | -28.4% | -30.4% | -61.7% | -230.8% | -135.5% | -46.0% | -44.0% | -56.3% | -84.9% | -63.0% |